Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

Go back to Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
METABASIS THERAPEUT (NASDAQ: MBRX) Delayed: 2.12 +0.04 (1.92%)
Previous Close $2.08    52 Week High $9.58 
Open $2.12    52 Week Low $2.34 
Day High $2.13    P/E N/A 
Day Low $2.07    EPS $-0.34 
Volume 44,412